Verition Fund Management
CUE icon

Verition Fund Management’s Cue Biopharma CUE Stock Holding History

Verition Fund Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-700
Closed -$76.7K – 2403
2023
Q2 		$76.7K Buy
+700
New +$82.3K ﹤0.01% 2003

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verition Fund Management's CUE Position: Q3 2023 in Review

Verition Fund Management sold out of Cue Biopharma (CUE) in Q3 2023, closing a stake of 700 shares — an estimated $76.7K sold.

Verition Fund Management first reported a position in CUE in Q2 2023 and held it in 1 quarter. The position peaked at $76.7K in Q2 2023. 75 funds tracked by Wall St. Rank hold CUE as of Q3 2023.

  • Verition Fund Management reported no remaining Cue Biopharma position as of Q3 2023 after selling out during the quarter.
  • Verition Fund Management sold 700 Cue Biopharma shares in Q3 2023, an estimated $76.7K.
  • Verition Fund Management first reported a position in Cue Biopharma in Q2 2023 and held it in 1 quarter.
  • Verition Fund Management's Cue Biopharma position peaked at $76.7K in Q2 2023.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2023.

Based on Verition Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.